Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase 2 trial of the minnie pearl cancer research network

Cancer

Volumn 112, Issue 6, 2008, Pages 1288-1295

  Hainsworth, John D ^a,b   Vazquez, Elizabeth R ^a   Spigel, David R ^a,b   Raefsky, Eric ^b   Bearden, James D ^c   Saez, Ruben A ^d   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Gibbs Cancer Center   (United States)

^d Watson Clinic   (United States)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Rituximab; Small lymphocytic lymphoma

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; CIMETIDINE; COTRIMOXAZOLE; DIPHENHYDRAMINE; FAMCICLOVIR; FLUDARABINE; PARACETAMOL; PETHIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; INJECTION SITE REACTION; LUNG INFILTRATE; LYMPHADENOPATHY; LYMPHATIC LEUKEMIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREMEDICATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL RATE; VIDARABINE;

EID: 41149101075     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23271     Document Type: Article

References (18)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
2. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparison analysis of CALGB9712 and CALGB9011. Blood. 2005;105:49-53.
3. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
4. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
5. Ludin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol. 1998;16:3257-3263.
6. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657-2663.
7. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab for minimal residual disease in CLL. Blood. 2003;102:109a. Abstract 371.
8. Hainsworth JD, Litchy S, Morrissey LH, et al. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1500-1506.
9. Cheson BD, Bennett JA, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1255.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. Cancer. 2006;107:2408-2416.
13. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24:2337-2342.
14. Schweighofer C, Ritgen M, Eichhorst B, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood. 2006;108:14a. Abstract 33.
15. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
16. Hillmen P, Skotnicki A, Robak T, et al. Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression-free survival vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). Blood. 2006;108:93a. Abstract 301.
17. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol. 1997;15:1567-1574.
18. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzimab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.